A Study Investigating Safety, Tolerability and Efficacy of Once-weekly NNC0662-0419 in Participants Living With Overweight or Obesity
Latest Information Update: 27 Oct 2025
At a glance
- Drugs NNC 06620419 (Primary)
- Indications Obesity
- Focus Adverse reactions; Therapeutic Use
- Sponsors Novo Nordisk
Most Recent Events
- 21 Oct 2025 Status changed from not yet recruiting to recruiting.
- 26 Sep 2025 New trial record